Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells

Experimental and Molecular Pathology

Volumn 94, Issue 2, 2013, Pages 372-379

  Kanzaki, Hirotaka ^a   Ohtaki, Akashi ^a   Merchant, Faisal K ^a   Greene, Mark I ^b   Murali, Ramachandran ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

K Ras; Osteoprotegerin; Pancreatic cancer; TNFRSF; TRAIL

Indexed keywords

MESSENGER RNA; OSTEOPROTEGERIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; SENSITIZATION; WESTERN BLOTTING;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL SURVIVAL; GENES, RAS; HUMANS; MUTATION; OSTEOPROTEGERIN; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84874473251     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.11.003     Document Type: Article

References (35)

1. Almasan A., Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine & Growth Factor Reviews 2003, 14:337-348.
2. Armstrong A.P., et al. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 2008, 68:92-104.
3. Benslimane-Ahmim Z., et al. Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. Journal of Thrombosis and Haemostasis 2011, 9:834-843.
4. Borad M.J., et al. Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature. The Yale Journal of Biology and Medicine 2009, 82:1-6.
5. Cross S.S., et al. Osteoprotegerin (OPG)-a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?. International Journal of Cancer 2006, 118:1901-1908.
6. Deramaudt T., Rustgi A.K. Mutant KRAS in the initiation of pancreatic cancer. Biochimica et Biophysica Acta 2005, 1756:97-101.
7. Drebin J.A., et al. Regulation of the immune response to antigens on the malignant cell surface. Springer Seminars in Immunopathology 1982, 5:175-192.
8. Emery J.G., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. The Journal of Biological Chemistry 1998, 273:14363-14367.
9. Ghaneh P., et al. Biology and management of pancreatic cancer. Gut 2007, 56:1134-1152.
10. Giehl K., et al. Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration. Oncogene 2000, 19:2930-2942.
11. Hansen M.B., et al. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. Journal of Immunological Methods 1989, 119:203-210.
12. Hingorani S.R., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4:437-450.
13. Hruban R.H., et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. The American Journal of Pathology 1993, 143:545-554.
14. Huang S., et al. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clinical Cancer Research 2009, 15:150-159.
15. Ibrahim S.M., et al. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 2001, 23:72-79.
16. Ji B., et al. Ras activity levels control the development of pancreatic diseases. Gastroenterology 2009, 137:1072-1082. (1082 e1-6).
17. Jones D.H., et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006, 440:692-696.
18. Kang S., et al. TRAIL upregulates decoy receptor 1 and mediates resistance to apoptosis in insulin-secreting INS-1 cells. Biochemical and Biophysical Research Communications 2010, 396:731-735.
19. Khanbolooki S., et al. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Molecular Cancer Therapeutics 2006, 5:2251-2260.
20. Kita K., et al. Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. International Journal of Cancer 1999, 80:553-558.
21. Liptay S., et al. Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. International Journal of Cancer 2003, 105:735-746.
22. Lipton A., et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clinical Cancer Research 2002, 8:2306-2310.
23. Mariani S.M., Krammer P.H. Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. European Journal of Immunology 1998, 28:1492-1498.
24. Martinez-Lorenzo M.J., et al. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. Journal of Immunology (Baltimore, Md.: 1950) 1999, 163:1274-1281.
25. Mori T., et al. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Surgery 2005, 138:71-77.
26. Mundy G.R. Mechanisms of bone metastasis. Cancer 1997, 80:1546-1556.
27. Rachner T.D., et al. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. Journal of Cellular Biochemistry 2009, 108:106-116.
28. Reid P.E., et al. Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact. Molecular Cancer 2009, 8:49.
29. Sahu R.P., et al. The role of K-ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines. Cancer Chemotherapy and Pharmacology 2011, 67:481-487.
30. Schuler S., et al. SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis. International Journal of Oncology 2011, 38:219-225.
31. Simonet W.S., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
32. Tominaga S., Kuroishi T. Epidemiology of pancreatic cancer. Seminars in Surgical Oncology 1998, 15:3-7.
33. Wang P., et al. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cellular Signalling 2007, 19:2237-2246.
34. Yagita H., et al. TRAIL and its receptors as targets for cancer therapy. Cancer Science 2004, 95:777-783.
35. Zauli G., et al. Role of full-length osteoprotegerin in tumor cell biology. Cellular and Molecular Life Sciences 2009, 66:841-851.